Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses

被引：5
|
作者：
Janjigian, Yelena Y.
Shitara, Kohei
Ajani, Jaffer
Moehler, Markus
Yao, Jin
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Schenker, Michael
Yanez, Patricio
Kowalyszyn, Ruben
Karamouzis, Michalis
Zander, Thomas
Feeney, Kynan
Elimova, Elena
Nathani, Raheel
Novosiadly, Ruslan
Lei, Ming
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT037
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648
    Chau, I.
    Ajani, J.
    Doki, Y.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C.
    Adenis, A.
    El Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, M.
    Holtved, E.
    Murphy, M. Blum
    Abdullaev, S.
    Soleymani, S.
    Lei, M.
    Kato, K.
    Kitagawa, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S379 - S380
  • [42] Q-TWiST analysis of nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC) in patients with PD-L1 CPS≥1 and CPS≥5: 4-year follow-up from CheckMate 649 (CM 649)
    Lin, D.
    Quan, W.
    Garretson, M.
    Chirikov, V. V.
    Chen, C.
    Singh, P.
    Davis, C.
    Sugarman, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S170 - S170
  • [43] Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
    Hirose, Toshiharu
    Yamamoto, Shun
    Kato, Ken
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [44] VARIATION IN HEALTH TECHNOLOGY ASSESSMENTS FOR NIVOLUMAB PLUS CHEMOTHERAPY VS CHEMOTHERAPY IN FIRST-LINE GASTRIC CANCER
    Bertwistle, D.
    Casabianca, P.
    Donvovan, L.
    Huetson, P.
    Okorogheye, G.
    Theodorou, E.
    Vezina, E.
    Villeneuve, J.
    Yoon, M. R.
    VALUE IN HEALTH, 2023, 26 (06) : S259 - S259
  • [45] Immunotherapy plus chemotherapy versus chemotherapy alone in the first-line treatment for advanced gastric cancer/gastroesophageal junction cancer: a real-world retrospective study
    Xu, Qian
    Yi, Dan
    Jia, Caiyan
    Kong, Fanming
    Jia, Yingjie
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [46] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649
    Moehler, M.
    Elimova, E.
    Blum, S., I
    Xiao, H.
    Davenport, E.
    Wang, J.
    Hunter, S.
    Li, M.
    Kondo, K.
    Wyrwicz, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 214 - 215
  • [47] Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial
    Shitara, Kohei
    Janjigian, Yelena Y.
    Ajani, Jaffer
    Moehler, Markus
    Yao, Jin
    Wang, Xuya
    Chhibber, Aparna
    Pandya, Dimple
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan
    Yamaguchi, Kensei
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Schenker, Michael
    Yanez, Patricio
    Kowalyszyn, Ruben
    Karamouzis, Michalis
    Zander, Thomas
    Feeney, Kynan
    Elimova, Elena
    Doshi, Parul
    Li, Mingshun
    Lei, Ming
    NATURE MEDICINE, 2025,
  • [48] EXPOSURE RESPONSE ANALYSES OF NIVOLUMAB AS ADJUVANT TREATMENT FOR PATIENTS WITH ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER (CHECKMATE 577).
    Zhao, Y.
    Tsujimoto, A.
    Ide, T.
    Zhu, L.
    Zhang, J.
    Feng, Y.
    Gao, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S60 - S60
  • [49] Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577
    Kelly, R.
    Moehler, M.
    Ajani, J.
    Yao, J.
    Kuzdzal, J.
    Zander, T.
    Van Cutsem, E.
    Piessen, G.
    Mendez, G.
    Feliciano, J.
    Motoyama, S.
    Lievre, A.
    Uronis, H.
    Elimova, E.
    Grootscholten, C.
    Geboes, K.
    Yang, Y.
    Zhang, J.
    Novosiadly, R.
    Cleary, J.
    Lei, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S183 - S183
  • [50] First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
    Hegewisch-Becker, Susanna
    Mendez, Guillermo
    Chao, Joseph
    Nemecek, Radim
    Feeney, Kynan
    Van Cutsem, Eric
    Al-Batran, Salah-Eddin
    Mansoor, Wasat
    Maisey, Nicholas
    Pazo Cid, Roberto
    Burge, Matthew
    Perez-Callejo, David
    Hipkin, R. William
    Mukherjee, Sourav
    Lei, Ming
    Tang, Hao
    Suryawanshi, Satyendra
    Kelly, Ronan J.
    Tebbutt, Niall C.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2080 - 2093
12345